MX2022006735A - Análogos de nucleósidos sustituidos como inhibidores de la prmt5. - Google Patents

Análogos de nucleósidos sustituidos como inhibidores de la prmt5.

Info

Publication number
MX2022006735A
MX2022006735A MX2022006735A MX2022006735A MX2022006735A MX 2022006735 A MX2022006735 A MX 2022006735A MX 2022006735 A MX2022006735 A MX 2022006735A MX 2022006735 A MX2022006735 A MX 2022006735A MX 2022006735 A MX2022006735 A MX 2022006735A
Authority
MX
Mexico
Prior art keywords
substituted nucleoside
nucleoside analogs
prmt5 inhibitors
prmt5
overexpression
Prior art date
Application number
MX2022006735A
Other languages
English (en)
Inventor
Prathap Sreedharan Nair
Ganesh Bhausaheb Gudade
Chaitanya Prabhakar Kulkarni
Milind Dattatraya Sindkhedkar
Venkata P Palle
Rajender Kumar Kamboj
Shankar Bhaskar Bhagwat
Amol Maruti Yadav
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2022006735A publication Critical patent/MX2022006735A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a análogos de nucleósidos sustituidos de fórmula (I), sales farmacéuticamente aceptables de los mismos y composiciones farmacéuticas para tratar enfermedades, trastornos o condiciones asociadas con la sobreexpresión de la enzima PRMT5. La invención también se refiere a métodos para tratar enfermedades, trastornos o condiciones asociadas con la sobreexpresión de la enzima PRMT5. (VER FORMULA).
MX2022006735A 2019-12-03 2020-12-02 Análogos de nucleósidos sustituidos como inhibidores de la prmt5. MX2022006735A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921049775 2019-12-03
PCT/IB2020/061372 WO2021111322A1 (en) 2019-12-03 2020-12-02 Substituted nucleoside analogs as prmt5 inhibitors

Publications (1)

Publication Number Publication Date
MX2022006735A true MX2022006735A (es) 2022-07-21

Family

ID=74004125

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006735A MX2022006735A (es) 2019-12-03 2020-12-02 Análogos de nucleósidos sustituidos como inhibidores de la prmt5.

Country Status (10)

Country Link
US (1) US20230066014A1 (es)
EP (1) EP4069698A1 (es)
JP (1) JP2023504279A (es)
CN (1) CN115135651A (es)
AU (1) AU2020394887A1 (es)
BR (1) BR112022010943A2 (es)
CA (1) CA3163421A1 (es)
MX (1) MX2022006735A (es)
WO (1) WO2021111322A1 (es)
ZA (1) ZA202205799B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3240963A1 (en) * 2021-12-23 2023-06-29 Steven Laplante Drug combinations for inhibiting coronavirus replication
WO2024074611A1 (en) * 2022-10-05 2024-04-11 Ryvu Therapeutics S.A. Prmt5 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011079236A1 (en) 2009-12-22 2011-06-30 The Ohio State University Research Foundation Compositions and methods for cancer detection and treatment
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
EP2935247B1 (en) 2012-12-21 2019-08-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
JP2016505001A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド Ｐｒｍｔ５阻害剤およびその使用
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム，インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用
KR102173874B1 (ko) 2012-12-21 2020-11-05 에피자임, 인코포레이티드 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도
GB201302927D0 (en) 2013-02-20 2013-04-03 Cancer Therapeutics Crc Pty Ltd Compounds
US9856218B2 (en) 2013-03-15 2018-01-02 Ohio State Innovation Foundation Inhibitors of PRMT5 and methods of their use
PE20170146A1 (es) 2014-06-25 2017-03-08 Glaxosmithkline Ip Dev Ltd Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida
EP3160466A4 (en) 2014-06-25 2017-12-27 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
WO2016022605A1 (en) 2014-08-04 2016-02-11 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
WO2016034671A1 (en) 2014-09-03 2016-03-10 Ctxt Pty Ltd Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors
US20180010132A1 (en) 2014-09-11 2018-01-11 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
JP6584521B2 (ja) 2015-02-24 2019-10-02 ファイザー・インク 抗がん剤として有用な置換ヌクレオシド誘導体
WO2016145150A2 (en) 2015-03-11 2016-09-15 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
AR104326A1 (es) 2015-05-04 2017-07-12 Lilly Co Eli Compuestos nucleósidos 5-sustituidos
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
WO2018015879A1 (en) * 2016-07-20 2018-01-25 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
WO2018085818A1 (en) 2016-11-07 2018-05-11 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
WO2018152501A1 (en) 2017-02-20 2018-08-23 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
EA201990851A1 (ru) 2017-02-24 2019-09-30 Янссен Фармацевтика Нв Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
US11098026B2 (en) 2017-03-13 2021-08-24 Impetis Biosciences Limited Fused bicyclic compounds, compositions and applications thereof
HRP20221207T1 (hr) * 2017-12-13 2022-12-09 Lupin Limited Supstituirani biciklički heterociklički spojevi kao inhibitori prmt5
MA53287A (fr) 2018-08-07 2022-05-11 Merck Sharp & Dohme Inhibiteurs de prmt5
BR112021019465A8 (pt) 2019-04-02 2022-06-07 Aligos Therapeutics Inc Compostos que têm como alvo prmt5

Also Published As

Publication number Publication date
AU2020394887A1 (en) 2022-06-16
CN115135651A (zh) 2022-09-30
WO2021111322A1 (en) 2021-06-10
US20230066014A1 (en) 2023-03-02
JP2023504279A (ja) 2023-02-02
BR112022010943A2 (pt) 2022-10-11
EP4069698A1 (en) 2022-10-12
CA3163421A1 (en) 2021-06-10
ZA202205799B (en) 2023-01-25

Similar Documents

Publication Publication Date Title
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
CR20230310A (es) Inhibidores de prmt5
MX2022014648A (es) Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b.
MX2022006700A (es) Compuestos poliheterociclicos como inhibidores de mettl3.
EA200702339A1 (ru) Замещенные амидные производные в качестве ингибиторов протеинкиназы
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2021012423A (es) Métodos y composiciones para degradación de proteínas específicas.
MX2022002219A (es) Triazolopirimidinas como inhibidores de a2a/a2b.
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2022006735A (es) Análogos de nucleósidos sustituidos como inhibidores de la prmt5.
ECSP22001370A (es) Inhibidores de prmt5
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
MX2021012749A (es) Inhibidor selectivo de la jak1 cinasa.
NZ746906A (en) Oxaborole esters and uses thereof
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MX2021014773A (es) Formas de sales cristalinas de un inhibidor de cinasas.
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
MX2022003340A (es) Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
MX2022002443A (es) Compuestos inhibidores de perk.
AU2020353055A8 (en) Antiviral pyrazolopyridinone compounds
EA202091424A1 (ru) Замещенные бициклические гетероциклические соединения в качестве ингибиторов prmt5